Bupropion hydrochloride (marketed as Wellbutrin, Zyban, and generics) Information
Bupropion hydrochloride is marketed under the following names:
-
Wellbutrin
-
Wellbutrin SR
-
Wellbutrin XL
-
Zyban
-
bupropion hydrochloride
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
Related Information
- FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
- FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg
- Questions and Answers Regarding Market Withdrawal of Budeprion XL 300 mg Manufactured by Impax and Marketed by Teva
- Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg
- Pharmacokinetic Assessment of Two Extended Release Prescription Products
- Division of Bioequivalence Review of Pharmacokinetic and Dissolution Data
- Bioequivalence Evaluation of Innovator and Generic Bupropion XL Products
- Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
- Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
- Podcast: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
- Antidepressant Use in Children, Adolescents, and Adults
- Information for Healthcare Professionals: Bupropion hydrochloride (marketed as the antidepressant Wellbutrin)
- Suicidality in Adults Being Treated with Antidepressant Medications
- Medication Guide for Antidepressant Drugs